Announced
Completed
Financials
Tags
Single Bidder
Completed
Friendly
United States
Acquisition
Private Equity
Private
biotechnology company
Venture Capital
Cross Border
Biotechnology
Minority
Synopsis
SoftBank Group, Heritage Provider Network, Irving Investors and Highside Capital Management led a $201m Series C round in InterVenn Biosciences, a biotechnology company, with participation from Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures. The proceeds from the financing will be used to accelerate development and commercialization of Dawn™, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.